Outlook Therapeutics (OTLK) Receivables (2015 - 2026)

Outlook Therapeutics (OTLK) reported Receivables of $2.7 million for Q1 2026, up 2273.14% quarter-over-quarter from $114609.0 in Q4 2025.

Outlook Therapeutics (OTLK) Receivables (2015 - 2026) Analysis & Trends

Outlook Therapeutics (OTLK) has 4 years of Receivables data on file, last reported at $2.7 million in Q1 2026.

Receivables for Q1 2026 came in at $2.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 million (changed N/A YoY), and the FY2025 annual result was $1.5 million, changed N/A from the prior year.
Receivables improved to $2.7 million in Q1 2026 per OTLK's latest filing, from $114609.0 in the prior quarter.
Over five years, Receivables peaked at $2.7 million in Q1 2026 and troughed at $114609.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	13.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	2.00 Bn
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Outlook Therapeutics	51.56 Mn	43.81 Mn	-21,888.00	2.72 Mn

Download Data